We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Gains From Solid Global Base, Headwinds Anticipated
Read MoreHide Full Article
On Feb 6, we issued an updated research report on Becton, Dickinson and Company (BDX - Free Report) , also known as BD. While solid developments and a strong global foothold boost the stock, a few headwinds are anticipated in fiscal 2019.
The stock currently carries a Zacks Rank #3 (Hold).
Price Performance
In the past year, BD’s shares have rallied 15% against the industry’s decline of 0.4%. The current level also compares favorably with the S&P 500’s rally of 6.5%.
Over the past 60 days, the Zacks Consensus Estimate for the company’s fiscal third-quarter earnings per share moved up 0.6% to $3.25.
In recent times, the New Jersey-based MedTech giant saw a slew of developments.
In the recently-reported first quarter of fiscal 2019, BD announced the launch of two cloud-based applications, BD HealthSight Data Manager and BD HealthSight Diversion Analytics, which enable an enterprise-wide connected medication management system. Notably, both form part of the BD HealthSight platform.
Moreover, in the BD Interventional segment, WavelinQ was made available for sale in the United States in the fiscal first quarter. This product provides a minimally-invasive nonsurgical option for creating critical AV fistulas for hemodialysis procedures.
Last month, BD announced the FDA approval of its second-generation BD Nano pen needle for more reliable subcutaneous injection depth. Last December, BD received regulatory approval for the BD MAX enteric viral panel, a molecular diagnostic test.
BD is focused on geographical expansion into overseas markets.
Notably, in first-quarter fiscal 2019, BD delivered strong sales internationally, which totaled $1.77 billion, up 24.6% from the year-ago quarter and 4.1% at constant currency (cc). Per management, overseas revenue growth was backed by strong performance by all three segments in the quarter.
China saw growth of 13.3% from the year-ago quarter, reflecting strength in the Life Science and Interventional segments. The core BD Medical segment excelled in China.
For fiscal 2019, BD expects growth of about 10% in emerging economies along with low double-digit growth in China.
Deterrents
Management at BD expects a few headwinds to mar prospects in fiscal 2019.
BD expects raw material pricing pressure, which increased in 2018, to accelerate into fiscal 2019, primarily due to resin price increases owing to a supply-constrained market. Although pressure from raw materials partially eased in the fiscal first quarter, management expects a 2% headwind from it in fiscal 2019.
Additionally, BD expects a 1% headwind from tariffs in 2019. Customer ordering patterns are also expected to negatively impact fiscal second-quarter results.
Penumbra’s long-term earnings growth rate is expected at 20%.
Wright Medical’s long-term earnings growth rate is expected at 11%.
DexCom’s next-quarter earnings per share is projected to grow at 56.3%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
BD Gains From Solid Global Base, Headwinds Anticipated
On Feb 6, we issued an updated research report on Becton, Dickinson and Company (BDX - Free Report) , also known as BD. While solid developments and a strong global foothold boost the stock, a few headwinds are anticipated in fiscal 2019.
The stock currently carries a Zacks Rank #3 (Hold).
Price Performance
In the past year, BD’s shares have rallied 15% against the industry’s decline of 0.4%. The current level also compares favorably with the S&P 500’s rally of 6.5%.
Over the past 60 days, the Zacks Consensus Estimate for the company’s fiscal third-quarter earnings per share moved up 0.6% to $3.25.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company Price and Consensus | Becton, Dickinson and Company Quote
What’s Favoring BD?
In recent times, the New Jersey-based MedTech giant saw a slew of developments.
In the recently-reported first quarter of fiscal 2019, BD announced the launch of two cloud-based applications, BD HealthSight Data Manager and BD HealthSight Diversion Analytics, which enable an enterprise-wide connected medication management system. Notably, both form part of the BD HealthSight platform.
Moreover, in the BD Interventional segment, WavelinQ was made available for sale in the United States in the fiscal first quarter. This product provides a minimally-invasive nonsurgical option for creating critical AV fistulas for hemodialysis procedures.
Last month, BD announced the FDA approval of its second-generation BD Nano pen needle for more reliable subcutaneous injection depth. Last December, BD received regulatory approval for the BD MAX enteric viral panel, a molecular diagnostic test.
BD is focused on geographical expansion into overseas markets.
Notably, in first-quarter fiscal 2019, BD delivered strong sales internationally, which totaled $1.77 billion, up 24.6% from the year-ago quarter and 4.1% at constant currency (cc). Per management, overseas revenue growth was backed by strong performance by all three segments in the quarter.
China saw growth of 13.3% from the year-ago quarter, reflecting strength in the Life Science and Interventional segments. The core BD Medical segment excelled in China.
For fiscal 2019, BD expects growth of about 10% in emerging economies along with low double-digit growth in China.
Deterrents
Management at BD expects a few headwinds to mar prospects in fiscal 2019.
BD expects raw material pricing pressure, which increased in 2018, to accelerate into fiscal 2019, primarily due to resin price increases owing to a supply-constrained market. Although pressure from raw materials partially eased in the fiscal first quarter, management expects a 2% headwind from it in fiscal 2019.
Additionally, BD expects a 1% headwind from tariffs in 2019. Customer ordering patterns are also expected to negatively impact fiscal second-quarter results.
Key Picks
A few better-ranked stocks in the broader medical space are Penumbra, Inc. (PEN - Free Report) , Wright Medical Group N.V. and DexCom. Inc. (DXCM - Free Report) . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s long-term earnings growth rate is expected at 20%.
Wright Medical’s long-term earnings growth rate is expected at 11%.
DexCom’s next-quarter earnings per share is projected to grow at 56.3%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>